Zoetis (ZTS) has an average broker rating of 1.8, which is interpreted as a Buy, as rated by 10 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 1, which is also a Strong Buy.
Zoetis (ZTS) : The highest short term price target forecast on Zoetis (ZTS) is $62 and the lowest target price is $45. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $53.13 with a standard deviation of $5.72.
For the current week, the company shares have a recommendation consensus of Buy.
Zoetis (NYSE:ZTS): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $48.53 and $48.22 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $48.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $48.87, notching a gain of 1.20% for the day. The total traded volume was 1,824,095 . The stock had closed at $48.29 on the previous day.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.